Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast mass21.05.04.002--Not Available
Breast neoplasm21.05.01.004; 16.10.02.0010.000313%Not Available
Breast pain21.05.05.0030.000689%
Bronchospasm22.03.01.004; 10.01.03.0120.000470%
Burning sensation17.02.06.001; 08.01.09.0290.001473%Not Available
Bursitis12.04.03.010; 15.04.01.0010.000689%Not Available
Calculus bladder20.04.03.001--Not Available
Calculus urinary20.04.03.0020.000313%Not Available
Cardiac hypertrophy02.04.02.0170.000313%Not Available
Cardiac tamponade02.06.01.0010.000470%
Cardiogenic shock24.06.02.006; 02.05.01.0030.000627%Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.0090.000313%Not Available
Carpal tunnel syndrome17.09.02.001--Not Available
Cataract06.06.01.001--
Catheter site related reaction12.07.02.001; 08.02.02.001--Not Available
Cervical dysplasia21.06.01.0020.001097%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills08.01.09.001; 15.05.03.0160.005295%
Cholangitis sclerosing10.04.09.002; 09.02.01.0030.000627%Not Available
Cholecystitis09.03.01.0010.000470%
Cholelithiasis09.03.01.0020.000940%Not Available
Cholestasis09.01.01.0010.002350%Not Available
Chromaturia20.02.01.0020.001535%
Chronic hepatitis11.07.01.009; 09.01.07.0210.000313%Not Available
Chronic lymphocytic leukaemia01.10.06.001; 16.01.06.0010.000783%Not Available
Chronic myeloid leukaemia16.01.07.001; 01.10.07.0010.000627%Not Available
Coagulopathy01.01.02.0010.002037%Not Available
Cold sweat08.01.03.024; 23.02.03.002--Not Available
Colitis07.08.01.0010.005859%
Colitis ulcerative10.02.01.004; 07.08.01.0050.009055%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene